RBC Capital lowered the firm’s price target on Aptose Biosciences to $23 from $40 after its Q2 earnings miss but keeps an Outperform rating on the shares. The quarter demonstrated progress of the APTIVATE expansion trial, with data cut showing appreciable efficacy of the tuspetinib doublet therapy in r/r AML patients previously failing venetoclax therapy, the analyst tells investors in a research note. RBC is adjusting its model however to account for Q2 updates, forecasting financing needs for program development.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on APTO:
- Aptose Biosciences price target lowered to $12 from $37 at Piper Sandler
- Aptose Biosciences price target lowered to $15 from $50 at Oppenheimer
- Aptose Biosciences reports Q2 EPS ($2.27), consensus(2.01)
- Aptose Reports Results for the Second Quarter 2023
- Aptose Biosciences (APTO) Q2 Earnings Cheat Sheet
